HomeCompareESAIY vs CL

ESAIY vs CL: Dividend Comparison 2026

ESAIY yields 3.13% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CL wins by $16.4K in total portfolio value· pulled ahead in Year 2
10 years
ESAIY
ESAIY
● Live price
3.13%
Share price
$7.66
Annual div
$0.24
5Y div CAGR
0.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.6K
Annual income
$400.49
Full ESAIY calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — ESAIY vs CL

📍 CL pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESAIYCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESAIY + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESAIY pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESAIY
Annual income on $10K today (after 15% tax)
$266.34/yr
After 10yr DRIP, annual income (after tax)
$340.42/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, CL beats the other by $4,293.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESAIY + CL for your $10,000?

ESAIY: 50%CL: 50%
100% CL50/50100% ESAIY
Portfolio after 10yr
$32.8K
Annual income
$2,926.10/yr
Blended yield
8.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

ESAIY
No analyst data
Altman Z
3.0
Piotroski
7/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESAIY buys
0
CL buys
9
PoliticianChamberTickerTypeAmountDate
John Boozman🏛 Senate$CL▼ Sell$1,001 - $15,0002025-10-09
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-10-07
Rick Larsen🏢 House$CL▼ Sell$1,001 - $15,0002025-10-06
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-09-29
Julie Johnson🏢 House$CL▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CL▼ Sell$1,001 - $15,0002025-09-11
Tim Moore🏢 House$CL▼ Sell$1,001 - $15,0002025-09-10
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-09-05
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-08-26
Lisa McClain🏢 House$CL▲ Buy$1,001 - $15,0002025-08-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESAIYCL
Forward yield3.13%2.44%
Annual dividend / share$0.24$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.4%28.6%
Portfolio after 10y$24.6K$41.0K
Annual income after 10y$400.49$5,451.69
Total dividends collected$3.6K$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ESAIY vs CL ($10,000, DRIP)

YearESAIY PortfolioESAIY Income/yrCL PortfolioCL Income/yrGap
1$11,015$314.60$11,014$313.84+$1.00ESAIY
2← crossover$12,111$325.14$12,200$415.44$89.00CL
3$13,294$335.45$13,607$553.09$313.00CL
4$14,570$345.51$15,301$741.41$731.00CL
5$15,945$355.31$17,374$1,002.00$1.4KCL
6$17,426$364.87$19,958$1,367.44$2.5KCL
7$19,020$374.16$23,243$1,887.87$4.2KCL
8$20,735$383.19$27,512$2,642.43$6.8KCL
9$22,578$391.97$33,197$3,759.22$10.6KCL
10$24,559$400.49$40,973$5,451.69$16.4KCL

ESAIY vs CL: Complete Analysis 2026

ESAIYStock

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESAIY Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this ESAIY vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESAIY vs SCHDESAIY vs JEPIESAIY vs OESAIY vs KOESAIY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.